Drug details:
Molecular formula: C₂₀H₁₉BrN₄O₃

Standard name: 1-(2-methoxyethyl)-2-methyl-3-(pyrazin-2-ylmethyl)benzo[f]benzimidazol-3-ium-4,9-dione;bromide

Synonyms:

YM155 YM155 (Sepantronium Bromide) Sepantronium (bromide) 4,9-Dihydro-1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(2-pyrazinylmethyl)-1H-naphth[2,3-d]imidazolium bromide 1-(2-methoxyethyl)-2-methyl-4,9-dioxo-3-(pyrazin-2-ylmethyl)-4,9-dihydro-1h-naphtho[2,3-d]imidazol-3-ium bromide 3-(2-METHOXYETHYL)-2-METHYL-4,9-DIOXO-1-(PYRAZIN-2-YLMETHYL)NAPHTHO[2,3-D]IMIDAZOL-1-IUM BROMIDE 1-(2-methoxyethyl)-2-methyl-3-(pyrazin-2-ylmethyl)benzo[f]benzimidazol-3-ium-4,9-dione bromide 3-(2-methoxyethyl)-2-methyl-4,9-dioxo-1-(pyrazin-2-ylmethyl)-4,9-dihydro-1H-naphtho[2,3-d]imidazol-3-ium bromide. ......

Curated SMILES: CC1=[N+](C2=C(N1CCOC)C(=O)C3=CC=CC=C3C2=O)CC4=NC=CN=C4.[Br-]

Evidence for compound's anti-virulence activity:

Escherichia
Related VF: TTSS secreted effectors
Target: NleB1
Drug effect: Inhibits the activity of Escherichia coli NleB1.
Max phase: Phase II trial
Publications:
El Qaidi S, et al., 2018. High-Throughput Screening for Bacterial Glycosyltransferase Inhibitors. Front Cell Infect Microbiol 8:435.
Zhu C, et al., 2021. YM155 Inhibits NleB and SseK Arginine Glycosyltransferase Activity. Pathogens 10(2):253.

Salmonella
Related VF: TTSS-2 secreted effectors
Target: SseK1/SseK2
Drug effect: Inhibits SseK1/SseK2 Arg glycosyltransferase activity.
Max phase: Preclinical (in vitro)
Publication:
Zhu C, et al., 2021. YM155 Inhibits NleB and SseK Arginine Glycosyltransferase Activity. Pathogens 10(2):253.